Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal Prevention of First Psychotic Episode (NAC + IPPI) in UHR Psychosis
DRKS00010952Phase 3Recruiting
- Sponsor
- Central Institute of Mental Health
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acetylcysteine in Schizophrenia Spectrum Disorders (SSD), Clinical high risk for psychosis (CHR), sponsored by Central Institute of Mental Health. Started Aug 2016; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Schizophrenia Spectrum Disorders (SSD)Clinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on DRKS00010952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010952.